In November, 2020, PRF brought over 370 registrants from 30 countries ‘together’ in our first-ever virtual scientific workshop. Attendees were given a platform to share their expertise in Progeria research and meet some of the children who will benefit from their...
We’re thrilled to share the results from two very exciting breakthrough studies on the use of RNA therapeutics in Progeria research. Both studies were co-funded by The Progeria Research Foundation (PRF) and co-authored by PRF’s Medical Director, Dr. Leslie Gordon....
Happy New Year! We hope everyone had a healthy, restful holiday. We are kicking off 2021 off with more exciting research news. In January, the science journal Nature published breakthrough results demonstrating that genetic editing in a mouse model of Progeria...
Breaking, exciting news! On November 20, 2020, PRF achieved an important piece of our mission: lonafarnib, the first-ever treatment for Progeria, has been granted FDA approval. Progeria now joins less than 5% of the rare diseases with an FDA-approved...
As we all navigate this uncertain time, our fight against Progeria remains steadfast. PRF staff and the clinical trial team have been working closely with our Progeria families around the world, to ensure their continued access to PRF’s vital services. Our programs...
Thank YOU! Through these uncertain times, one thing is certain: The Progeria Research Foundation is still working tirelessly to help families impacted by Progeria. PRF is there for the children and their families from day one, so for this year’s ONEpossible Campaign,...
